Spero Therapeutics, Inc.Spero Therapeutics, Inc.Spero Therapeutics, Inc.

Spero Therapeutics, Inc.

No trades
See on Supercharts

SPRO fundamentals

Spero Therapeutics, Inc. key financial stats and ratios

SPRO price-to-sales ratio is 0.68. The company has an Enterprise Value to EBITDA ratio of 1.60. As of 2023 they employed 46 people.

Statistics
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
‪0.00‬
Price to earnings ratio
Price to cash flow ratio
Currency: USD
Q3 '17
Q4 '17
Q1 '18
Q2 '18
Q3 '18
Q4 '18
Q1 '19
Q2 '19
Q3 '19
Q4 '19
Q1 '20
Q2 '20
Q3 '20
Q4 '20
Q1 '21
Q2 '21
Q3 '21
Q4 '21
Q1 '22
Q2 '22
Q3 '22
Q4 '22
Q1 '23
Q2 '23
Q3 '23
Q4 '23
Q1 '24
Q2 '24
Current
Key stats
Valuation ratios
Profitability ratios
Liquidity ratios
Solvency ratios